Abstract
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases characterized by asymmetric left ventricular hypertrophy (LVH). Advances in diagnosis and management have made HCM a manageable disease with reduced morbidity and mortality. The clinical course of HCM mainly derives from studies in tertiary HCM centers. However, these studies are limited due to gaps in follow-up between clinical encounters or loss of follow-up as local physicians resume care.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
